A new study has found that Nexavar, a drug used for the treatment of kidney and liver cancer, can substantially raise blood pressure. According to the authors of the study, published in U.K. medical journal Lancet Oncology, patients on Nexavar (sorafenib) should be closely monitored and treated for high blood pressure in order to prevent cardiovascular problems.

Nexavar, which is being co-developed by Bayer AG and Onyx Pharmaceuticals Inc., is now being reviewed for treating small-cell lung cancer, prostate cancer and melanoma. Bayer said the drug’s high-blood-pressure risks are covered by the labeling.